Imagine a simple, low-dose pill that could help people with mild COPD breathe a little better. A year-long study in China tested this idea, giving over 700 patients either a low dose of theophylline—a common, inexpensive medication—or a placebo. The main finding was a small but measurable improvement in how much air patients could forcefully exhale before using a rescue inhaler. The improvement averaged about 30 milliliters, which is roughly the volume of a shot glass.
But here's the catch that matters most to patients: the drug did not reduce the annual rate of exacerbations—those scary and damaging flare-ups of coughing and breathlessness. The rate of these events was virtually identical between the drug and placebo groups. This is a crucial point because preventing these flare-ups is a primary goal of COPD treatment.
The study found the low dose was well-tolerated, with side effects comparable to the placebo. However, the overall picture is mixed. While the lung function signal is positive, its real-world importance is unclear because it didn't translate into fewer bad episodes. The researchers themselves note that larger trials are needed to fully understand if this small benefit is meaningful for people living with COPD.